Breast Cancer :: Glaxo’s Tykerb drug delays spread of breast cancer
GlaxoSmithKline’s new drug Tykerb dramatically slows the spread of aggressive late-stage breast cancer. Data from a Phase III study reporting that Tykerb? (lapatinib) plus Xeloda? (capecitabine) is superior to capecitabine alone in women with HER2 (ErbB2) positive advanced breast cancer who had progressed following prior therapy, including Herceptin? (trastuzumab), was published today in the New England Journal of Medicine (NEJM).